Candel Therapeutics Inc (CADL) Return on Investment ROI from the second quarter of 2026 to second quarter of 2025 and for the year 2026, average high and low, overall ranking from Jun 30 2026 to Jun 30 2025 - CSIMarket
Candel Therapeutics Inc's ROI from its second quarter of 2026 to the second quarter of 2025 and 5 Year Period
Return on Investment, Quarterly Results, Trends, Rankings, Statistics
What is Candel Therapeutics Inc's ROI in the second quarter of 2026?
Candel Therapeutics Inc recorded a cumulative net loss of $-89 million during 12 months ending in the second quarter of 2026, resulting in a negative return on investment (ROI) of -60.06%.
Within the Healthcare sector 304 other companies had a higher return on investment. While return on investment, the total ranking has deteriorated compared to the first quarter of 2026 from 3566 to 3628.
Candel Therapeutics, Inc. a clinical-stage biopharmaceutical company, has made significant strides in the development of its multimodal biological immunotherapies for cancer treatment. Recent announcements about preclinical data for CAN-3110 in melanoma and convincing phase 2 results for CAN-2409 in non-small cell lung cancer (NSCLC) suggest a bright future for both compounds, potentially expanding Candel’s therapeutic horizon and solidifying its position in the competitive oncology market. Cancer remains a formidable challenge in the field of medicine, demanding innovative therapeutic approaches. Candel Therapeutics, committed to developing multifaceted biological immunotherapies, has showcased exciting advancements with two distinct candidates: CAN-3110 and CAN-2409. This article presents the key findings from the recent announcements and evaluates their implications for Candel Therapeutics moving forward.
In the rapidly advancing field of oncology, Candel Therapeutics, Inc. (Nasdaq: CADL), emerges as a beacon of innovation and hope. With a steadfast commitment to developing multimodal biological immunotherapies, the clinical-stage biopharmaceutical company is making significant strides in the realm of cancer treatment. Recent announcements highlight the company’s upcoming presentations at prominent oncology meetings and the promising status of its therapeutic candidates, CAN-3110 and CAN-2409. Groundbreaking Research PresentationsCandel Therapeutics is poised to present pivotal preclinical data on its promising candidate CAN-3110 at the Society for Immunotherapy of Cancers (SITC) 39th Annual Meeting, scheduled for November 6-10, 2024, in Houston, Texas. The focus of the presentation will center on the therapeutic potential of CAN-3110 in treating melanoma, a notoriously aggressive form of skin cancer. This presentation represents a critical moment for Candel as it showcases their commitment to addressing significant unmet medical needs within oncology.
Candel Therapeutics Joins Russell 3000 Index, Despite Cumulative Net Loss Candel Therapeutics, a clinical stage biopharmaceutical company focused on cancer immunotherapies, has announced its inclusion in the broad-market Russell 3000 Index. The decision was made during the 2024 Russell US Indexes annual reconstitution, with the company set to join the index at the open of US equity markets on July 1, 2024. This development was based on a preliminary list of additions published on May 24, 2024. Despite its achievement, Candel Therapeutics Inc has experienced a cumulative net loss of $-32 million in the 12-month period ending in the third quarter of 2023. This has resulted in a negative return on investment (ROI) of -56.92%. In comparison, among companies within the Healthcare sector, there are 618 others that have shown higher ROIs.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
